Organ Preservation Patents: Who Leads, Where the Gaps Are 2026
- Concentrated at the top. the top 5 of 7 ranked assignees together hold 87.0% of all 23 records in scope, with a single leader at 9 filings.
- Filing activity peaked in 2021. at 11 records, and had fallen back to zero by the 2022 midpoint, a pattern worth checking against your own timing assumptions.
- Every record touches A01N. biocide and preservation-solution claims (100.0% of records), while A61K medicinal-preparation claims sit at 26.1% – a much thinner second layer.
What this patent set covers
This landscape draws on 23 published records filed between 2015 and 2026 that combine organ preservation, machine perfusion or normothermic perfusion language in the title or abstract with claims touching cold ischemia time extension, viability assessment during perfusion, perfusate composition, portable logistics devices or expanded criteria donor utilization. The IPC scope is anchored on A01N1 (preserving bodies, organs or tissue), A61M1 (devices for introducing media into the body) and A61B17 (surgical instruments), which keeps the set focused on preservation and perfusion hardware and chemistry rather than transplant surgery generally.
Because publication lags filing by roughly 18 months, the most recent filing years in this dataset understate real activity – a 2026 count of zero reflects the reporting gap, not a stop in R&D. Patent families, not raw document counts, are the fairer unit for judging real filing volume here, since a single invention can generate several publications across jurisdictions.
Filing trends and technology composition
Two views of the same 23-record set: the year-by-year filing curve, and the IPC subclasses that define where the claims actually sit.
A single-peak filing curve
Filings were absent in 2017, built toward a peak of 11 records in 2021, then fell to zero by 2022 and have stayed flat since – a shape more consistent with a burst of activity around a specific technical push than a steadily growing field.
One dominant class, several thin adjacents
A01N (biocides and organ/tissue preservation) appears in 100.0% of the 23 records, meaning it is effectively the entry ticket for this search scope. A61K (medicinal preparations) trails at 26.1%, and A61L, C07K and G01N each sit at 8.7% – each of these thinner classes carries only 2 records, so claim space there is far less occupied.
Shares are the percentage of the 23 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Organ Preservation and Transplantation Technology with Eureka
This page is one run against one query. Ask Eureka your own question about organ preservation and transplantation technology and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited records in this set
Organ preservation device (US20260150832A1)
A system for ex vivo normothermic organ preservation built around a pump circulating perfusate through a perfusion circuit, an oxygenator, a heat exchanger regulating perfusate temperature, and an organ chamber sized to receive an organ. The circuit connects to an arterial inlet into the organ, and a processor with stored instructions carries out a temperature-change method – moving the perfusate from an initial temperature through a defined protocol.Filed by The Regents of the University of California, published 2026-06-04.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20220408720A1 | Apparatus and Method for Sustaining and Evaluating Isolated Organs | 3 |
| 2 | WO2022017763A1 | Organ preservation and/or perfusion solution | 2 |
| 3 | WO2024018051A1 | Stable plasmin compositions for organ preservation and reconditioning | 1 |
Citation counts favour older records that have had more time to accumulate citations within this searched corpus; treat them as a signal of influence rather than current importance.
Publication numbers are shown where the record carries one (3 of 3 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Read together, the concentration figures, the filing curve and the IPC spread point to a field where the core preservation-chemistry claim space is heavily occupied but several adjacent branches are not.
A narrow leadership group, not a fragmented field
With 7 ranked assignees accounting for all 23 records, and the top 5 alone holding 87.0%, this is not a landscape of many small independent filers. A new entrant is more likely to run into an existing claim from one of the established players than from a long tail of unrelated actors.
Activity clustered around a single window
The filing curve rose to 11 records in 2021 and dropped to zero by the 2022 midpoint, with no rebound through the most recent complete years. That is a flat-or-declining pattern rather than steady growth, though the 18-month publication lag means the very latest years are always undercounted.
One class carries the whole field
Every record in this set carries an A01N classification, confirming that preservation-solution and biocide-type claims are the common denominator. The much thinner A61L, C07K and G01N shares (8.7% each, 2 records apiece) mark where claim density drops off sharply.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to organ preservation and transplantation technology, with the prior art for and against each one.
Who holds the claims
Seven assignees account for the entire ranked set, with filing activity that has gone quiet across the board in the most recent year – a useful cue to check whether competitors have shifted to trade secrecy, licensing, or simply paused.
A single filer well ahead of the field
The top-ranked assignee holds 9 of the 23 records in scope, well clear of the fifth-place holder at 2. That gap is the clearest single fact in this dataset for anyone mapping freedom to operate.
No active filer in the most recent year
Every assignee in the ranking, including the academic filers, shows zero filings in the latest year, with the University of California board recording a -100% year-on-year change. Given the 18-month publication lag, this likely understates true current activity rather than confirming the field has gone cold.
Corporate, academic and individual filers side by side
The ranked list mixes medical-device companies with university research offices and at least one named individual inventor, holding roughly comparable volumes at the lower end of the ranking. That mix suggests licensing and sponsored-research routes are as relevant here as direct competitive filing.
| Assignee | Recent year | YoY |
|---|---|---|
| Xiweiwo Medical Technology Co., Ltd. | 0 | — |
| Griffor Global Operations Limited | 0 | — |
| Atec Medical Limited | 0 | — |
| Saint Louis University | 0 | — |
| The Regents of the University of California | 0 | -100% |
| BRASSIL JOHN M | 0 | — |
| The Regents of the University of Michigan | 0 | -100% |
Where to take this analysis
The dataset points to a concentrated leadership group and several thin adjacent classes – the next step is usually to pressure-test both against your own draft claims.
Check freedom to operate against the leader
With one assignee holding 9 of 23 records, a claim chart against that portfolio should come before any drafting work in the core A01N preservation-solution space.
Run a freedom-to-operate checkExplore the thinner IPC branches
A61L, C07K and G01N each cover only 2 of the 23 records – worth a closer look if your invention sits in sterilisation, peptide additives or viability testing rather than the core preservation solution.
Explore white space in EurekaCommon questions about organ preservation patents
Within this 23-record dataset, one assignee leads with 9 records, well ahead of the fifth-ranked holder at 2. The top 5 of the 7 ranked assignees together account for 87.0% of all records in scope, so the field is concentrated rather than fragmented among many independent filers. Anyone assessing competitive position or freedom to operate in this space should start by charting claims against that leading portfolio before looking further down the ranking.
Filing activity in this dataset peaked at 11 records in 2021 and dropped to zero by the 2022 midpoint, staying flat through the most recent complete years. That is a flat-to-declining pattern rather than sustained growth. It is worth remembering that publication typically lags filing by around 18 months, so the very latest years in any such dataset will always look thinner than they eventually turn out to be once more filings publish.
Every one of the 23 records in this set carries an A01N classification, covering biocides and methods for preserving organs, bodies or tissue – effectively the entry point for this technology area. A61K, covering medicinal preparations, appears in 26.1% of records, a much smaller share. Sterilising and disinfecting methods (A61L), peptide and protein compositions (C07K), and material analysis and testing (G01N) each appear in only 8.7% of records, marking them as thinner, less-occupied branches relative to the core preservation-chemistry claims.
The clearest signal in this dataset is the gap between the near-universal A01N preservation-chemistry claims and the much thinner adjacent classes – A61L sterilisation, C07K peptide compositions, and G01N viability testing each cover only 2 of the 23 records. Portable logistics housings and real-time viability sensing during perfusion also sit outside the dense core. These branches are not necessarily easy to patent, but they carry far less prior art density than the central perfusate-composition and preservation-method claims that the leading assignees already occupy.
US20260150832A1, titled Organ preservation device, was filed by The Regents of the University of California and published on 2026-06-04. It describes a normothermic ex vivo perfusion system built around a pump, oxygenator, heat exchanger and organ chamber, controlled by a processor that executes a temperature-change protocol on the circulating perfusate. Anyone designing a perfusion system with automated temperature control over an arterial-inlet circuit should review this filing's claim scope directly rather than relying on the abstract alone, since system-level claims of this kind can be broad.
Research Organ Preservation and Transplantation Technology in depth with Eureka
Go past this page: query the whole organ preservation and transplantation technology corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.